Evaluation of therapeutic effect on prostate cancer patients with bone metastases using Bone Scan Index (BSI)

Evaluation of therapeutic effect on prostate cancer patients with bone metastases using Bone Scan Index (BSI) - Evaluation of therapeutic effect of prostate cancer by BSI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011648

Enrollment

160

Registered

2013-09-04

Start date

2013-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer patients with bone metastasis

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Male patients who were histologically diagnosed as prostate cancer 2.Patients who underwent 99mTc-MDP bone scintigraphy and have more than one bone metastasis 3.Patients who expects more than 6 months life 4. Patients older than 20 years 5.Patients who offered written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with difficulty in bone scintigraphy data analsysis due to the structural deformity or extraosseous uptake in bone scintigraphy 2. Patients corresponding to contraindication of Tc 99m methylene diphosphonate 3.Patient who were inappropriate for this study judged by medical doctor

Design outcomes

Primary

Measure	Time frame
The change rate of BSI before and after treatment	—

Secondary

Measure	Time frame
The correlation between change rate of BSI and SRE event rate The correlation between change rate of BSI and PSA, bone turnover markers	—

Countries

Japan

Contacts

Public ContactMotohide Uemura

Osaka University Graduate School of Medicine Department of Organ Specific Regulation (Urology)

uemura@uro.med.osaka-u.ac.jp81668793531

Outcome results